References
- Abarca K, Rey-Jurado E, Muñoz-Durango N et al. (2020) Safety and immunogenicity evaluation of recombinant BCG vaccine against respiratory syncytial virus in a randomized, double-blind, placebo-controlled phase I clinical trial. EClinicalMedicine 27:100517.
https://doi.org/10.1016/j.eclinm.2020.100517 - Aberle JH, Aberle SW, Dworzak MN et al. (1999) Reduced interferon-gamma expression in peripheral blood mononuclear cells of infants with severe respiratory syncytial virus disease. Am J Respir Crit Care Med 160:1263–1268.
https://doi.org/10.1164/ajrccm.160.4.9812025 - Akter S, Roy AS, Tonmoy MIQ et al. (2022) Deleterious single nucleotide polymorphisms (SNPs) of human IFNAR2 gene facilitate COVID-19 severity in patients: a comprehensive in silico approach. J Biomol Struct Dyn 40:11173–11189.
https://doi.org/10.1080/07391102.2021.1957714 - Antunes KH, Fachi JL, de Paula R et al. (2019) Microbiota-derived acetate protects against respiratory syncytial virus infection through a GPR43-type 1 interferon response. Nat Commun 10:3273.
https://doi.org/10.1038/s41467-019-11152-6 - Arts RJ, Blok BA, Aaby P et al. (2015) Long-term in vitro and in vivo effects of γ-irradiated BCG on innate and adaptive immunity. J Leukoc Biol 98:995–1001.
https://doi.org/10.1189/jlb.4ma0215-059R - Arts RJW, Carvalho A, La Rocca C et al. (2016) Immunometabolic pathways in BCG-induced trained immunity. Cell Rep 17:2562–2571.
https://doi.org/10.1016/j.celrep.2016.11.011 - Arts RJW, Moorlag SJCFM, Novakovic B et al. (2018) BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity. Cell Host Microbe 23:89–100.e5.
https://doi.org/10.1016/j.chom.2017.12.010 - Bessière P, Wasniewski M, Picard-Meyer E et al. (2021) Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model. PLoS Pathog 17:e1009427.
https://doi.org/10.1371/journal.ppat.1009427 - Beyer DK, Forero A (2022) Mechanisms of antiviral immune evasion of SARS-CoV-2. J Mol Biol 434:167265.
https://doi.org/10.1016/j.jmb.2021.167265 - Biering-Sørensen S, Aaby P, Napirna BM et al. (2012) Small randomized trial among low-birth-weight children receiving bacillus Calmette–Guérin vaccination at first health center contact. Pediatr Infect Dis J 31:306–308.
https://doi.org/10.1097/INF.0B013E3182458289 - Blasius AL, Beutler B (2010) Intracellular toll-like receptors. Immunity 32:305–315.
https://doi.org/10.1016/j.immuni.2010.03.012 - Bont L, Heijnen CJ, Kavelaars A et al. (2001) Local interferon-gamma levels during respiratory syncytial virus lower respiratory tract infection are associated with disease severity. J Infect Dis 184:355–358.
https://doi.org/10.1086/322035 - Chen J, Liu J, Chen Z et al. (2022) Angiotensin-converting enzyme 2 potentiates SARS-CoV-2 infection by antagonizing type I interferon induction and its down-stream signaling pathway. mSphere 7:e0021122.
https://doi.org/10.1128/msphere.00211-22 - Chong Z, Karl CE, Halfmann PJ et al. (2022) Nasally delivered interferon-λ protects mice against infection by SARS-CoV-2 variants including Omicron. Cell Rep 39:110799.
https://doi.org/10.1016/j.celrep.2022.110799 - Corral-Fernández NE, Cortez-Espinosa N, Salgado-Bustamante M et al. (2016) Induction of transcription factors, miRNAs and cytokines involved in T lymphocyte differentiation in BCG-vaccinated subjects. Mol Immunol 77:44–51.
https://doi.org/10.1016/j.molimm.2016.07.006 - Díaz FE, Guerra-Maupome M, McDonald PO et al. (2021) A recombinant BCG vaccine is safe and immunogenic in neonatal calves and reduces the clinical disease caused by the respiratory syncytial virus. Front Immunol 12:664212.
https://doi.org/10.3389/fimmu.2021.664212 - Eichinger KM, Egaña L, Orend JG et al. (2015) Alveolar macrophages support interferon gamma-mediated viral clearance in RSV-infected neonatal mice. Respir Res 16:122.
https://doi.org/10.1186/S12931-015-0282-7 - Faustman DL, Lee A, Hostetter ER et al. (2022) Multiple BCG vaccinations for the prevention of COVID-19 and other infectious diseases in type 1 diabetes. Cell Rep Med 3:100728.
https://doi.org/10.1016/j.xcrm.2022.100728 - Hijano DR, Vu LD, Kauvar LM et al. (2019) Role of type I interferon (IFN) in the respiratory syncytial virus (RSV) immune response and disease severity. Front Immunol 10:566.
https://doi.org/10.3389/fimmu.2019.00566 - Hilligan KL, Namasivayam S, Clancy CS et al. (2022) Intravenous administration of BCG protects mice against lethal SARS-CoV-2 challenge. J Exp Med 219:e20211862.
https://doi.org/10.1084/jem.20211862 - Hilligan KL, Namasivayam S, Clancy CS et al. (2023) Bacterial-induced or passively administered interferon gamma conditions the lung for early control of SARS-CoV-2. Nat Commun 14:8229.
https://doi.org/10.1038/s41467-023-43447-0 - Kaufmann E, Khan N, Tran KA et al. (2022) BCG vaccination provides protection against IAV but not SARS-CoV-2. Cell Rep 38:110502.
https://doi.org/10.1016/j.celrep.2022.110502 - Kaufmann E, Sanz J, Dunn JL et al. (2018) BCG educates hematopoietic stem cells to generate protective innate immunity against tuberculosis. Cell 172:176–190.e19.
https://doi.org/10.1016/j.cell.2017.12.031 - Kaur BP, Secord E (2021) Innate immunity. Immunol Allergy Clin North Am 41:535–541.
https://doi.org/10.1016/j.iac.2021.07.003 - Kleinnijenhuis J, Quintin J, Preijers F et al. (2012) Bacille Calmette–Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci USA 109:17537–17542.
https://doi.org/10.1073/PNAS.1202870109 - Kleinnijenhuis J, Quintin J, Preijers F et al. (2014) Long-lasting effects of BCG vaccination on both heterologous Th1/Th17 responses and innate trained immunity. J Innate Immun 6:152–158.
https://doi.org/10.1159/000355628 - Lalor MK, Floyd S, Gorak-Stolinska P et al. (2011) BCG vaccination induces different cytokine profiles following infant BCG vaccination in the UK and Malawi. J Infect Dis 204:1075–1085.
https://doi.org/10.1093/infdis/jir515 - Lalor MK, Smith SG, Floyd S et al. (2010) Complex cytokine profiles induced by BCG vaccination in UK infants. Vaccine 28:1635–1641.
https://doi.org/10.1016/j.vaccine.2009.11.004 - Leentjens J, Kox M, Stokman R et al. (2015) BCG vaccination enhances the immunogenicity of subsequent influenza vaccination in healthy volunteers: a randomized, placebo-controlled pilot study. J Infect Dis 212:1930–1938.
https://doi.org/10.1093/infdis/jiv332 - Li JY, Liao CH, Wang Q et al. (2020) The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway. Virus Res 286:198074.
https://doi.org/10.1016/j.virusres.2020.198074 - Liu BM, Li NL, Wang R et al. (2024a) Key roles for phosphorylation and the Coiled-coil domain in TRIM56-mediated positive regulation of TLR3-TRIF–dependent innate immunity. J Biol Chem 300:107249.
https://doi.org/10.1016/j.jbc.2024.107249 - Liu BM, Rakhmanina NY, Yang Z et al. (2024b) Mpox (Monkeypox) virus and its co-infection with HIV, sexually transmitted infections, or bacterial superinfections: double whammy or a new prime culprit? Viruses 16:784.
https://doi.org/10.3390/V16050784 - Lo MS, Brazas RM, Holtzman MJ (2005) Respiratory syncytial virus nonstructural proteins NS1 and NS2 mediate inhibition of Stat2 expression and alpha/beta interferon responsiveness. J Virol 79:9315–9319.
https://doi.org/10.1128/JVI.79.14.9315-9319.2005 - Marr N, Wang TI, Kam SH et al. (2014) Attenuation of respiratory syncytial virus-induced and RIG-I-dependent type I IFN responses in human neonates and very young children. J Immunol 192:948–957.
https://doi.org/10.4049/jimmunol.1302007 - Mitroulis I, Ruppova K, Wang B et al. (2018) Modulation of myelopoiesis progenitors is an integral component of trained immunity. Cell 172:147–161.e12.
https://doi.org/10.1016/J.cell.2017.11.034 - Moorlag SJCFM, Arts RJW, van Crevel R et al. (2019) Non-specific effects of BCG vaccine on viral infections. Clin Microbiol Infect 25:1473–1478.
https://doi.org/10.1016/j.cmi.2019.04.020 - Mukherjee S, Subramaniam R, Chen H et al. (2017) Boosting efferocytosis in alveolar space using BCG vaccine to protect host against influenza pneumonia. PLoS One 12:e0180143.
https://doi.org/10.1371/journal.pone.0180143 - Netea MG, Quintin J, Van Der Meer JWM (2011) Trained immunity: a memory for innate host defense. Cell Host Microbe 9:355–361.
https://doi.org/10.1016/j.chom.2011.04.006 - Nguyen LS, Ait Hamou Z, Gastli N et al. (2021) Potential role for interferon gamma in the treatment of recurrent ventilator-acquired pneumonia in patients with COVID-19: a hypothesis. Intensive Care Med 47:619–621.
https://doi.org/10.1007/S00134-021-06377-3 - Ogger PP, Garcia Martín M, Michalaki C et al. (2022) Type I interferon receptor signalling deficiency results in dysregulated innate immune responses to SARS-CoV-2 in mice. Eur J Immunol 52:1768–1775.
https://doi.org/10.1002/eji.202249913 - Ramaswamy M, Shi L, Varga SM et al. (2006) Respiratory syncytial virus nonstructural protein 2 specifically inhibits type I interferon signal transduction. Virology 344:328–339.
https://doi.org/10.1016/j.virol.2005.09.009 - Sir Karakus G, Tastan C, Dilek Kancagi D et al. (2021) Preclinical efficacy and safety analysis of gamma-irradiated inactivated SARS-CoV-2 vaccine candidates. Sci Rep 11:5804.
https://doi.org/10.1038/S41598-021-83930-6 - Starr SE, Visintine AM, Tomeh MO et al. (1976) Effects of immunostimulants on resistance of newborn mice to herpes simplex type 2 infection. Proc Soc Exp Biol Med 152:57–60.
https://doi.org/10.3181/00379727-152-39327 - Stensballe LG, Nante E, Jensen IP et al. (2005) Acute lower respiratory tract infections and respiratory syncytial virus in infants in Guinea-Bissau: a beneficial effect of BCG vaccination for girls community based case-control study. Vaccine 23:1251–1257.
https://doi.org/10.1016/j.vaccine.2004.09.006 - Sviridov D, Miller YI, Bukrinsky MI (2022) Trained immunity and HIV infection. Front Immunol 13:903884.
https://doi.org/10.3389/fimmu.2022.903884 - Thieme CJ, Anft M, Paniskaki K et al. (2020) Robust T cell response toward spike, membrane, and nucleocapsid SARS-CoV-2 proteins is not associated with recovery in critical COVID-19 patients. Cell Rep Med 1:100092.
https://doi.org/10.1016/j.xcrm.2020.100092 - Uthayakumar D, Paris S, Chapat L et al. (2018) Non-specific effects of vaccines illustrated through the BCG example: from observations to demonstrations. Front Immunol 9:100092.
https://doi.org/10.3389/fimmu.2018.02869 - van Laarhoven A, Kurver L, Overheul GJ et al. (2021) Interferon gamma immunotherapy in five critically ill COVID-19 patients with impaired cellular immunity: a case series. Med 2:1163–1170.e2.
https://doi.org/10.1016/j.medj.2021.09.003 - Vanderheiden A, Ralfs P, Chirkova T et al. (2020) Type I and Type III interferons restrict SARS-CoV-2 infection of human airway epithelial cultures. J Virol 94:e985–e920.
https://doi.org/10.1128/JVI.00985-20 - Weir RE, Black GF, Nazareth B et al. (2006) The influence of previous exposure to environmental mycobacteria on the interferon-gamma response to bacille Calmette–Guérin vaccination in southern England and northern Malawi. Clin Exp Immunol 146:390–399.
https://doi.org/10.1111/J.1365-2249.2006.03222.X - Znaidia M, Demeret C, van der Werf S et al. (2022) Characterization of SARS-CoV-2 evasion: interferon pathway and therapeutic options. Viruses 14:1247.
https://doi.org/10.3390/V14061247